News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UCB Group (UCBJF.PK) And Sanofi-Aventis (France) (SASY.PA) Sign A Co-Promotion Agreement For Xyzal(R); In The United States


9/25/2006 4:44:18 PM

BRUSSELS, BELGIUM -- (MARKET WIRE) -- September 25, 2006 -- UCB and sanofi-aventis announced today that they have entered into an agreement to co-promote in the United States the prescription antihistamine medicine, Xyzal® (levocetirizine dihydrochloride). Xyzal® is a once-daily antihistamine which was first launched in Europe in 2001 and currently marketed in 49 countries around the world where it enjoys leadership position in key markets.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES